TABLE 2.
Univariate analyses and LASSO regression analysis for 1‐year graft loss
| A | 1‐year graft survival, % | Univariate | ||
|---|---|---|---|---|
| Variables | P value | OR | 95%CI | |
| Recipient factor | ||||
| Sex: male (vs female) | 89.2 (vs 89.9) | 0.80 | 1.08 | 0.59‐2.00 |
| Age (vs <40 years) | (vs 88.1) | 0.51 | 1.30 | 0.60‐2.82 |
| 40‐59 years | 90.9 | 0.39 | 0.74 | 0.38‐1.46 |
| ≥60 years | 87.3 | 0.86 | 1.08 | 0.45‐2.58 |
| Primary liver disease (vs acute liver failure) | (vs 86.6) | reference | ||
| Cirrhosis (hepatocellular, viral) | 88.3 | 0.70 | 0.85 | 0.38‐1.92 |
| Cirrhosis (hepatocellular, non–viral) | 89.5 | 0.59 | 0.76 | 0.28‐2.08 |
| Cirrhosis (cholestatic, BA) | 91.3 | 0.37 | 1.62 | 0.57‐4.61 |
| Cirrhosis (cholestatic, non–BA) | 80.0 | 0.30 | 0.62 | 0.25‐1.53 |
| Metabolic disease | 100.0 | 1.00 | 0.00 | 0.0–∞ |
| Others | 100.0 | 1.00 | 0.00 | 0.0–∞ |
| Re–transplantation: yes (vs no) | 77.6 (vs 92.0) | <0.001 | 3.29 | 1.71‐6.35 |
| Ascites: moderate (vs none‐mild) | 87.2 (vs 91.8) | 0.11 | 1.64 | 0.89‐3.04 |
| Encephalopathy: ≥Ⅲ (vs ≤Ⅱ) | 82.8 (vs 90.5) | 0.08 | 1.99 | 0.93‐4.27 |
| Medical condition: in ICU (vs not in ICU) | 83.3 (vs 91.9) | 0.01 | 2.28 | 1.23‐4.22 |
| Dialysis: yes (vs no) | 89.0 (vs 90.0) | 0.76 | 1.11 | 0.56‐2.19 |
| Anti‐hepatitis C antibody positive (vs negative) | 90.7 (vs 89.3) | 0.69 | 0.85 | 0.38‐1.90 |
| BMI (vs <25.0 kg/m2) | (vs 90.4) | reference | ||
| 25.0‐34.9 kg/m2 | 86.8 | 0.29 | 1.44 | 0.74‐2.81 |
| ≥35.0 kg/m2 | 100.0 | 1.00 | 0.00 | 0.0–∞ |
| MELD score (vs <20) | (vs 91.5) | |||
| 20‐29 | 91.4 | 0.96 | 1.02 | 0.48‐2.17 |
| 30‐39 | 82.4 | 0.05 | 2.31 | 1.00‐5.36 |
| ≥40 | 72.7 | 0.06 | 4.06 | 0.95‐17.4 |
| Donor factor | ||||
| Sex: male (vs female) | 89.7 (vs 89.2) | 0.87 | 0.95 | 0.52‐1.75 |
| Age (vs <40 years) | (vs 90.9) | reference | ||
| 40‐59 years | 91.8 | 0.76 | 0.90 | 0.44‐1.83 |
| 60‐69 years | 81.7 | 0.06 | 2.25 | 0.97‐5.21 |
| ≥70 years | 40.0 | 0.004 | 15.0 | 2.3‐97.0 |
| Hypertension: yes (vs no) | 91.4 (vs 89.0) | 0.74 | 0.87 | 0.39‐1.94 |
| Diabetes mellites: yes (vs no) | 100.0 (vs 89.1) | 1.00 | 0.00 | 0–∞ |
| BMI (vs <25.0 kg/m2) | (vs 90.6) | reference | ||
| 25.0‐34.9 kg/m2 | 85.1 | 0.13 | 1.69 | 0.87‐3.30 |
| ≥35.0 kg/m2 | 100.0 | 1.00 | 0.00 | 0–∞ |
| Alcohol history: yes (vs no) | 87.8 (vs 89.8) | 0.21 | 2.07 | 0.66‐6.46 |
| Smoking history: yes (vs no) | 90.9 (vs 89.1) | 0.54 | 0.82 | 0.44‐1.54 |
| Anti‐hepatitis B core antibody positive (vs negative) | 91.5 (vs 89.3) | 0.64 | 0.78 | 0.27‐2.27 |
| Cause of death (vs Trauma) | (vs 89.3) | reference | ||
| Cerebrovascular disease | 88.3 | 0.80 | 1.11 | 0.49‐2.48 |
| Anoxia | 91.3 | 0.62 | 0.80 | 0.33‐1.95 |
| Others | 100.0 | 1.00 | 0.00 | 0.0–∞ |
| Duration on respirator (vs <7 days) | (vs 90.1) | reference | ||
| 7‐27 days | 88.9 | 0.69 | 1.13 | 0.61‐2.11 |
| ≥28 days | 92.3 | 0.80 | 0.76 | 0.09‐6.16 |
| Catecholamine index (vs <10.0) | (vs 91.8) | reference | ||
| 10.0‐29.9 | 84.1 | 0.04 | 2.11 | 1.04‐4.26 |
| ≥30.0 | 63.6 | 0.005 | 6.38 | 1.77‐23.1 |
| Sodium, maximum (vs <160 mEq/L) | (vs 91.2) | reference | ||
| 160‐179 mEq/L | 87.6 | 0.23 | 1.47 | 0.78‐2.77 |
| ≥180 mEq/L | 75.0 | 0.07 | 3.45 | 0.88‐13.6 |
| Sodium, last ≥160 mEq/L (vs <160 mEq/L) | 88.9 (vs 89.6) | 0.11 | 1.03 | 0.99‐1.06 |
| Total bilirubin, maximum (vs <3.0 mg/dL) | (vs 91.1) | reference | ||
| 3.0‐4.9 mg/dL | 82.4 | 0.10 | 2.20 | 0.86‐5.69 |
| ≥5.0 mg/dL | 70.0 | 0.004 | 4.41 | 1.59‐12.2 |
| Total bilirubin, last (vs <3.0 mg/dL) | (vs 91.1) | reference | ||
| 3.0‐4.9 mg/dL | 80.8 | 0.12 | 2.27 | 0.81‐6.34 |
| ≥5.0 mg/dL | 70.0 | 0.12 | 2.85 | 0.75‐10.8 |
| AST, maximum (vs <100 IU/L) | (vs 89.0) | reference | ||
| 100‐999 IU/L | 90.8 | 0.55 | 0.82 | 0.43‐1.56 |
| ≥1000 IU/L | 82.1 | 0.30 | 1.76 | 0.60‐5.15 |
| AST, last ≥100 IU/L (vs <100 IU/L) | 86.9 (vs 89.9) | 0.47 | 1.35 | 0.60‐3.05 |
| ALT, maximum (vs <100 IU/L) | (vs 89.1) | reference | ||
| 100‐999 IU/L | 90.3 | 0.68 | 0.88 | 0.47‐1.63 |
| ≥1000 IU/L | 86.7 | 0.77 | 1.25 | 0.27‐5.87 |
| ALT, last ≥100 IU/L (vs <100 IU/L) | 87.9 (vs 89.8) | 0.67 | 1.20 | 0.51‐2.83 |
| GGT, maximum ≥150 IU/L (vs <150 IU/L) | 87.3 (vs 91.0) | 0.25 | 1.46 | 0.77‐2.80 |
| GGT, last ≥150 IU/L (vs <150 IU/L) | 86.7 (vs 90.6) | 0.31 | 1.47 | 0.71‐3.05 |
| Creatinine, last ≥1.5 mg/dL (vs <1.5 mg/dL) | 89.3 (vs 89.6) | 0.94 | 1.03 | 0.48‐2.23 |
| Image findings of steatosis: present (vs absent) | 89.3 (vs 91.1) | 0.71 | 0.82 | 0.28‐2.40 |
| Number of declines for donor reason ≥3 (vs <3) | 82.5 (vs 90.2) | 0.13 | 1.96 | 0.81‐4.71 |
| Surgical factor | ||||
| Split liver transplantation: yes (vs no) | 91.9 (vs 89.3) | 0.63 | 0.74 | 0.22‐2.50 |
| Simultaneous liver and kidney transplantation: yes (vs no) | 100.0 (vs 89.1) | 1.00 | 0.00 | 0–∞ |
| Total ischemic time (vs <9.0 h) | (vs 95.2) | reference | ||
| 9.0‐10.9 h | 90.3 | 0.08 | 2.12 | 0.91‐4.96 |
| 11.0‐12.9 h | 77.0 | <0.001 | 5.91 | 2.62‐13.3 |
| ≥13.0 h | 68.2 | <0.001 | 9.25 | 3.13‐27.3 |
| Others | ||||
| Transplantation era (vs Era1) | (vs 84.7) | reference | ||
| Era2 | 87.6 | 0.52 | 0.79 | 0.37‐1.65 |
| Era3 | 93.9 | 0.02 | 0.38 | 0.17‐0.87 |
| B | Coefficient β | OR exp (β) |
|---|---|---|
| Variables | ||
| Recipient factor | ||
| Re–transplantation: yes (vs no) | 0.545 | 1.724 |
| Encephalopathy: ≥Ⅲ (vs ≤Ⅱ) | 0.000 | 1.000 |
| Medical condition: in ICU (vs not in ICU) | 0.383 | 1.466 |
| MELD score (vs <20) | reference | |
| 20‐29 | 0.000 | 1.000 |
| 30‐39 | 0.291 | 1.338 |
| ≥40 | 0.473 | 1.605 |
| Donor factor | ||
| Age (vs <40 years) | reference | |
| 40‐59 years | 0.000 | 1.000 |
| 60‐69 years | 0.390 | 1.476 |
| ≥70 years | 0.869 | 2.385 |
| Catecholamine index (vs <10.0) | reference | |
| 10.0‐29.9 | 0.262 | 1.300 |
| ≥30.0 | 0.642 | 1.901 |
| Sodium, maximum (vs <160 mEq/L) | reference | |
| 160‐179 mEq/L | 0.000 | 1.000 |
| ≥180 mEq/L | 0.518 | 1.678 |
| Total bilirubin, maximum (vs <3.0 mg/dL) | reference | |
| 3.0‐4.9 mg/dL | 0.079 | 1.082 |
| ≥5.0 mg/dL | 0.544 | 1.723 |
| Surgical factor | ||
| Total ischemic time (vs <9.0 h) | reference | |
| 9.0‐10.9 h | 0.000 | 1.000 |
| 11.0‐12.9 h | 0.923 | 2.541 |
| ≥13.0 h | 1.152 | 3.164 |
| Others | ||
| Transplantation era (vs Era1) | reference | |
| Era2 | 0.000 | 1.000 |
| Era3 | – 0.170 | 0.842 |
| Intercept | – 2.876 | 0.056 |
Bold emphasis indicates variables with P values <0.10 in the univariate analyses (A) and variables with non‐zero coefficient in the LASSO analysis (B). Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BA, biliary atresia; BMI, body mass index; CI, confidential intervals; GGT, gamma‐glutamyl transpeptidase; ICU, intensive care unit; LASSO, the least absolute shrinkage and selection operator; MELD, Model for End‐stage Liver Disease.